Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12124297 | 0.90 | MEN1 (0.56) | KMT2AMEN1SMN1; SMN2HTTLOXL2 | |
| SCHEMBL12121132 | 0.81 | POLB (0.53) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL14243219 | 0.81 | SMN1; SMN2 (0.50) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL12121122 | 0.78 | HTT (0.57) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL12121118 | 0.78 | LOXL2 (0.51) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL15095650 | 0.78 | EGLN1 (0.46) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL12121033 | 0.77 | LOXL2 (0.49) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL24386505 | 0.77 | SMN1; SMN2 (0.47) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL3867188 | 0.77 | SMN1; SMN2 (0.47) | KMT2AMEN1SMN1; SMN2HTTNPC1 | |
| SCHEMBL12121026 | 0.77 | HTT (0.74) | KMT2AMEN1SMN1; SMN2HTTLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | KMT2A 2734/4885MEN1 4376/4885SMN1; SMN2 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.